Related Experiment Video
Updated: Jul 19, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Predictive and prognostic markers in human glioblastomas
Kamalakannan Palanichamy1, Michael Erkkinen, Arnab Chakravarti
1Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA.
Current Treatment Options in Oncology
|October 13, 2006
Summary
Glioblastoma patients with MGMT promoter methylation showed improved outcomes with temozolomide and radiation therapy. This suggests personalized glioblastoma treatment based on tumor genetics is promising.
Area of Science:
- Neuro-oncology
- Cancer Genomics
- Clinical Trials
Background:
- Glioblastomas (GBMs) are highly aggressive brain tumors with poor prognoses.
- Current treatments including surgery, radiation, and chemotherapy offer limited survival benefits.
- The addition of temozolomide (TMZ) to radiation therapy has become a standard of care, but not all patients benefit.
Purpose of the Study:
- To investigate the role of MGMT promoter methylation in predicting response to temozolomide and radiation therapy in glioblastoma patients.
- To explore the potential for molecular profiling to guide personalized glioblastoma treatment strategies.
Main Methods:
- Retrospective analysis of a phase III clinical trial data.
- Correlative study assessing MGMT promoter methylation status in glioblastoma tumors.
- Evaluation of patient outcomes based on MGMT methylation status and treatment received.
Main Results:
- GBM patients with MGMT promoter methylated tumors demonstrated a significantly greater benefit from the addition of temozolomide to radiation therapy compared to those without methylation.
- These findings suggest a potential biomarker for treatment response.
Conclusions:
- MGMT promoter methylation status may predict response to temozolomide in glioblastoma.
- Personalized treatment approaches tailored to individual tumor molecular profiles hold promise for improving glioblastoma outcomes.
- Prospective validation is necessary before clinical implementation of MGMT methylation for patient stratification.
